Overall rank by patents
#12,818
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Astrazeneca UK Limited
USPTO PatentsView assignee record - 23 granted patents across 8 technology areas, active 2016–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G16H (HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA).
23
Total patents granted
8
CPC technology areas
24.1
Avg claims per patent
+260%
5-year filing velocity
The verdict
Astrazeneca holds 23 US patents across 8 technology areas, rank #12,818 of 50,000 tracked assignees.
- #12,818
- of 50,000 US assignees by volume
- Top 8%
- by Innovation Score (54.1/100)
- 24.1
- avg claims per patent
- +260%
- filing velocity, last 5 yrs
Portfolio overview
AstraZeneca UK Limited has been granted 23 US utility patents between 2016 and 2024, placing AstraZeneca UK Limited at rank #12,818 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 24.1 claims per patent with primary concentration in G16H (HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA). As a Foreign Corporation, AstraZeneca UK Limited is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 54.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 18 grants, compared with 5 in the 2015–2019 window, a +260% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. AstraZeneca UK Limited's 24.1 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 8 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark AstraZeneca UK Limited against peers pursuing similar technology classes.
How does AstraZeneca compare?
Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Astrazeneca UK ◀ 23
AstraZeneca UK Limited
23 patents
What this shows AstraZeneca holds 23 patents, placing it at rank #12,818 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
AstraZeneca's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
54 Top 8% higher than 92% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2016–2024
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 4.3% |
| 2017 | 2 | 8.7% |
| 2018 | 1 | 4.3% |
| 2019 | 1 | 4.3% |
| 2020 | 1 | 4.3% |
| 2021 | 3 | 13.0% |
| 2022 | 5 | 21.7% |
| 2023 | 6 | 26.1% |
| 2024 | 3 | 13.0% |
Which technologies does AstraZeneca UK Limited patent most?
Top 8 of 8 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Accelerating
Frequently Asked Questions
How many patents does AstraZeneca UK Limited hold?
AstraZeneca UK Limited holds 23 US granted patents filed between 2016 and 2024, spanning 8 technology areas.
What is AstraZeneca UK Limited's Innovation Score?
AstraZeneca UK Limited has an Innovation Score of 54.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does AstraZeneca UK Limited focus on?
AstraZeneca UK Limited's top technology area is G16H (HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA) with 18 patents. The company has filed patents in 8 CPC subclasses total.
Is AstraZeneca UK Limited's patent filing rate increasing or decreasing?
AstraZeneca UK Limited's recent filing velocity is +260% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for AstraZeneca UK Limited's patents?
AstraZeneca UK Limited's patents average 24.1 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the AstraZeneca UK Limited patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Guides to patent portfolio analysis
How to use this portfolio
Astrazeneca's 23 grants land it in the top 8% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Astrazeneca ranks #12,818 of 50,000. Top 50 holders
- Most of this portfolio concentrates in G16H - see who else leads that technology area. G16H leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
G16H technology
AstraZeneca UK Limited's primary CPC class, all holders and yearly trends
Top 50 patent holders
See where AstraZeneca UK Limited ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov
